3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
55
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasms
14
Pancreatic Neoplasms
11
Uveal Melanoma
10
Prostatic Neoplasms
10
Leukemia, Myeloid, Acute
9
Squamous Cell Carcinoma of Head and Neck
7
Sarcoma
7
Myelodysplastic Syndromes
7
Lymphoma
7
Lung Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Recurrence
5
Myeloproliferative Disorders
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Glioblastoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Interventions
Gemcitabine
6
pembrolizumab
5
toripalimab
2
fludarabine
2
Valproic Acid
2
Valganciclovir
2
Injections
2
Cyclophosphamide
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tislelizumab
1
spartalizumab
1
sapropterin
1
fosaprepitant
1
fludarabine phosphate
1
camrelizumab
1
Surgical Procedures, Operative
1
Specimen Handling
1
SHR-1701
1
Protons
1
Proton Therapy
1
Panobinostat
1
Medicare Part B
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-2
1
Floxuridine
1
Everolimus
1
Dexamethasone
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Nasopharyngeal Carcinoma
×
Ipilimumab
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled